These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8879889)

  • 21. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching patients from clozapine to risperidone therapy.
    Zimbroff DL
    Am J Psychiatry; 1995 Jul; 152(7):1102. PubMed ID: 7540802
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical significance of drug binding, protein binding, and binding displacement drug interactions.
    Jann MW
    Psychopharmacol Bull; 2002; 36(3):22-41. PubMed ID: 12473962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone.
    Hendouei N; Farnia S; Mohseni F; Salehi A; Bagheri M; Shadfar F; Barzegar F; Hoseini SD; Charati JY; Shaki F
    Biomed Pharmacother; 2018 Jul; 103():965-972. PubMed ID: 29710513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.
    Bondolfi G; Dufour H; Patris M; May JP; Billeter U; Eap CB; Baumann P
    Am J Psychiatry; 1998 Apr; 155(4):499-504. PubMed ID: 9545995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of risperidone and olanzapine on the indications for clozapine.
    Ganguli R; Brar JS
    Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M; Kuwilsky A; Krumm B; Dressing H
    J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
    Ren XS; Qian S; Lee AF; Herz L; Miller DR; Kazis LE
    J Clin Pharm Ther; 2006 Feb; 31(1):57-65. PubMed ID: 16476121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Withdrawal from clozapine: the "rebound phenomenon".
    Durst R; Teitelbaum A; Katz G; Knobler HY
    Isr J Psychiatry Relat Sci; 1999; 36(2):122-8. PubMed ID: 10472746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clozapine-withdrawal catatonia.
    Wadekar M; Syed S
    Psychosomatics; 2010; 51(4):355-355.e2. PubMed ID: 20587767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risperidone versus other atypical antipsychotic medication for schizophrenia.
    Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
    Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.
    Chouinard G; Vainer JL; Bélanger MC; Turnier L; Beaudry P; Roy JY; Miller R
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Nov; 18(7):1129-41. PubMed ID: 7531355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Supersensitivity psychosis in a case with clozapine tolerance.
    Ozcan S; Soydan A; Tamam L
    Eur Rev Med Pharmacol Sci; 2012 Oct; 16 Suppl 4():70-3. PubMed ID: 23090814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study.
    Machielsen MW; Veltman DJ; van den Brink W; de Haan L
    J Psychopharmacol; 2014 Jul; 28(7):633-42. PubMed ID: 24646809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
    J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?
    Suzuki T; Takeuchi H; Watanabe K
    J Clin Psychiatry; 2010 Nov; 71(11):1553-4; author reply 1554. PubMed ID: 21114953
    [No Abstract]   [Full Text] [Related]  

  • 40. Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature.
    Ke CL; Yen CF; Chen CC; Yang SJ; Chung W; Yang MJ
    Kaohsiung J Med Sci; 2004 Jun; 20(6):295-301. PubMed ID: 15253471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.